Clinical Trials Logo
  1. Home
  2. Degenerative Osteoarthritis
  3. NCT01335243

Efficacy and Safety Study of Lumbar Interbody Fusion With MatriTMBONE Associated With Autologous Bone Marrow — MatriBone  

Degenerative Osteoarthritis Clinical Trial

Official title:
Multicentric, Prospective Study of Efficacy and Safety of Lumbar Interbody Fusion With MatriTMBONE Associated With Autologous Marrow

Clinical Trial Summary

The main objective of this clinical study is the estimation of the rate of intersomatic fusion observed 12 months after lumbar interbody fusion by posterior approach with PEEK interbody cage of fusion in PEEK performed with autologous bone of decortication and osseous substitute with a biomaterial (MatriBONE associated with the autologous bone marrow), associated with a posterolateral bone graft performed with MatriBone waxed with bone marrow. Indication is dedicated for patients by painful degenerative osteoarthritis, by narrow lumbar canal and\or spondylolisthesis.

Clinical Trial Description

This clinical study corresponds to a TLIF surgery using a per-operating artificial substitute specific biomaterial: autologous osteoblasts punctured on iliac crest and put on a collagen support waxed with tri-calcium phosphate (which is osteoconductive) to perform a intervertebral body fusion. Biomaterial MATRITM BONE: Device of class III, with marking IT in the indication of arthrodesis. It will be administered during the lumbar interbody fusion's procedure. The material is a matrix of collagen mineralized containing a homogeneous mixture of collagen cleansed of type I+III and an osseous biphasic substitute HA / TCP. The proportion of both constituents is 90 % of osseous substitute for 10 % of collagen en masse. The collagen is reduced in approximately 1 month and the osseous substitute leads to an osseous reshaping in 6 - 9 months approximately. The follow up will last 12 months with 2 visits (6 and 12 months after surgery), 2 CT scan slides before inclusion and at 12 months, classical X-rays before inclusion and at 6 and 12 months, questionnaires (visual analogic scale for pain, and quality of life with OSWESTRY and SF36 scales) before inclusion and at 6 and 12 months, and biological exams (CRP/VS, for inflammation) at each visit. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01335243
Study type Interventional
Source University Hospital, Bordeaux
Contact
Status Completed
Phase Phase 2
Start date May 2011
Completion date June 30, 2015
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05302934 - Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty
Active, not recruiting NCT03203330 - A Study to Determine the Safety and Efficacy of TG-C in Subjects With Kellgren and Lawrence Grade 2 or 3 OA of the Knee Phase 3
Not yet recruiting NCT05276011 - A Study to Determine the Safety and Efficacy of TG-C in Subjects With Symptomatic Early Hip Osteoarthritis Phase 2
Active, not recruiting NCT03685110 - CoreHip - Post Market Clinical Follow-Up Study
Recruiting NCT05742763 - Platelet-Rich Plasma and the Effects of NSAIDs on Pain and Functional Scores in Knee Osteoarthritis Phase 1/Phase 2
Completed NCT02802085 - VEGA Prospective Kiel
Completed NCT02756702 - All Polyethylene Tibia-VEGA Kiel
Not yet recruiting NCT02776943 - UCMSC Transplantation in the Treatment of Cartilage Damage Phase 1/Phase 2
Completed NCT01626677 - Follow-Up Study of CARTISTEM® Versus Microfracture for the Treatment of Knee Articular Cartilage Injury or Defect Phase 3
Completed NCT01413061 - Study of Subtalar Arthrodesis Using AlloStem® Versus Autologous Bone Graft N/A
Completed NCT06254976 - Serum Nesfatin-1 and Human Cartilage Glycoprotein-39 Levels in Knee Osteoarthritis N/A
Recruiting NCT05427019 - Continuous Distal Adductor Canal Block With Periarticular Local Anesthetic Infiltration Versus Continuous Distal Adductor Canal Block Alone for Analgesia After Total Knee Arthroplasty N/A
Completed NCT03817632 - Orthopilot Elite Post-Market Clinical Follow-Up
Recruiting NCT02687399 - Determine the Efficacy of TT-173. Reducing the the Total Blood Loss Associated With Total Knee Arthroplasty (HESTAT) Phase 2/Phase 3
Recruiting NCT03849885 - Cutibacterium Dermal Colonization: Implications for Total Hip Arthroplasty Phase 4
Completed NCT03442855 - Non-Interventional, Multicenter Bicontact® E PMCF Study
Active, not recruiting NCT03291470 - Study to Determine the Efficacy and Safety of TG-C in Subjects With Kellgren/Lawrence Grade 2 or 3 OA of the Knee Phase 3
Completed NCT05291130 - AESCULAP® Plasmafit® Cementless Acetabular System With Vitelene® Vitamin E Stabilized Highly Crosslinked Polyethylene
Active, not recruiting NCT04255966 - Plasmafit® Revision Structan® Hip Endoprosthesis Cup